Let's focus on what we can do!

Facebook Twitter Instagram Linkedin
What are you looking for?

By Disabled People for Disabled People

  • Home
  • >
  • Latest Headlines
  • >
  • FDA Rejects PTC’s New Drug Application for Translarna as a Nonsense Mutation DMD Treatment – Muscular Dystrophy News

FDA Rejects PTC’s New Drug Application for Translarna as a Nonsense Mutation DMD Treatment – Muscular Dystrophy News

Friday, 26 February, 2016

Categories

FDA Rejects PTC’s New Drug Application for Translarna as a Nonsense Mutation DMD Treatment – Muscular Dystrophy News

Ataluren is a small-molecule protein restoration therapy compound in clinical development for the treatment of Duchenne muscular dystrophy (DMD) caused by a nonsense mutation (nmDMD), cystic fibrosis caused by a nonsense mutation (nmCF), and other ...

Read More

Source:FDA Rejects PTC's New Drug Application for Translarna as a Nonsense Mutation DMD Treatment - Muscular Dystrophy News

Categories :
  • Latest Headlines , 
  • Muscular Dystrophy , 
  • Uncategorized
Socials :

Recent posts

@abilitytoday
Let's share our
memories
@abilitytodayuk
Let's be
friends
@abilitytoday
Let's chat and hear
your voice
@ability-today
Let's get down to
Business
Ability Today to your inbox.

By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.

Our Awards and Partners

Disability confident Logo
Donate to Ability Today CIC
(A Social Enterprise)

Copyright © 2023 All rights reserved

Facebook Twitter Instagram Linkedin